WO1998009964A1 - IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE - Google Patents

IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE Download PDF

Info

Publication number
WO1998009964A1
WO1998009964A1 PCT/US1997/015007 US9715007W WO9809964A1 WO 1998009964 A1 WO1998009964 A1 WO 1998009964A1 US 9715007 W US9715007 W US 9715007W WO 9809964 A1 WO9809964 A1 WO 9809964A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
equivalents
reaction
compound
reagent
Prior art date
Application number
PCT/US1997/015007
Other languages
French (fr)
Inventor
Gregory S. Bisacchi
Joseph E. Sundeen
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to AU40906/97A priority Critical patent/AU4090697A/en
Publication of WO1998009964A1 publication Critical patent/WO1998009964A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems

Definitions

  • This invention is directed to improvements in several steps of the process disclosed by Zahler et al . in U.S. Patent 5,206,244 for preparing the antiviral agent of the formula
  • One improvement involves the step where the protected guanine substituted cyclopentanol compound of the formula (VI )
  • Pi is a trityl or substituted trityl protecting group such as monomethoxytrityl or 4, 4 ' -dimethoxytrityl is oxidized to the keto compound of the formula
  • the oxidation is achieved by reacting the cyclopentanol of formula VI with Dess-Martin periodinane having the formula
  • the keto compound of formula VIII is obtained in higher yields than in the process of example 1(g) of U.S. Patent 5,206,244.
  • Another improvement involves the step where the keto compound of formula VIII is converted to the methylene compound of the formula
  • methylenation of the keto group is achieved by use of the Nysted reagent having the formula
  • Patent 5,206,244 the antiviral agent of formula I is prepared by treating the cyclopentenol of the formula
  • the epoxide of formula III can then be treated to introduce a benzyl protecting group onto the hydroxy.
  • the epoxide of formula III in tetrahydrofuran can be added to a suspension of sodium hydride in tetrahydrofuran followed by the addition of benzyl bromide and tetrabutyl-ammonium iodide to give the epoxide of the formula
  • the protected epoxide of formula IV can then be reacted with O-benzyl guanine to give the guanine substituted cyclopentanol of the formula
  • the amino group of the guanine substituted cyclopentanol of formula V can then be protected with trityl or substituted trityl to give the protected guanine substituted cyclopentanol of formula VI.
  • the compound of formula VI wherein Pi is monomethoxytrityl can be obtained by treating a solution of the compound of formula V in dichloromethane with triethylamine followed by p-anisylchlorodiphenylmethane and 4-dimethylamino-pyridine.
  • the compound of formula VI can then be oxidized to keto compound of formula VIII.
  • the yield of the keto compound of formula VIII is increased by employing the Dess-Martin periodinane of formula VII as the oxidizing agent.
  • the protected guanine substituted cyclopentanol of formula VI can be reacted with from about 1 to about 4 equivalents, preferably about 2 equivalents, of the Dess-Martin periodinane of formula VII at a temperature of from about -20°C to about 40°C, preferably at about room temperature, i.e. about 22 °C.
  • the reaction is performed in a suitable solvent such as dichloromethane, chloroform, 1, 2-dichloroethane, other chlorinated hydrocarbons, or acetonitrile.
  • Preferred solvents include dichloromethane, chloroform, and 1, 2-dichloroethane with dichloromethane being most preferred.
  • water or t-butanol can be included in the reaction mixture at up to about 1 equivalent of the Dess-Martin periodinane, preferably about 1 equivalent of t-butanol is included in the reaction mixture.
  • the reaction can be run for about 30 minutes to about 24 hours but will usually be completed in about 2 hours .
  • the keto compound of formula VIII can then be methylenated to the methylene compound of formula XI .
  • the yield of the methylene compound of formula XI is increased by the use of the Nysted reagent of formula IX, the Tebbe reagent of formula X, or the zinc reagent described by Takai et al . (J. Org. Chem., 1994, 5_9_, p. 2668 - 2670 and supplementary material) as the methylenation reagent.
  • the Nysted reagent of formula IX is the preferred methylenation reagent.
  • the methylenation is performed with the Nysted reagent of formula IX
  • from about 1 to about 4 equivalents of the Nysted reagent are employed per equivalent of the keto compound of formula VIII, preferably about 1.3 equivalents of Nysted reagent.
  • Up to about 1 equivalent of titanium tetrachloride per equivalent of the keto compound of VIII can be also included in the reaction mixture, preferably 1 equivalent of titanium tetrachloride.
  • the keto compound of formula VIII and the Nysted reagent of formula IX can be reacted in a suitable solvent such as tetrahydrofuran or hexamethylphosphoramide, preferably tetrahydrofura .
  • the reaction can be kept at a temperature of from about -78°C to about 25°C during the initial mixing and then at from about 0°C to the reflux temperature of the solvent, e.g. 66°C for tetrahydrofuran, preferably at room temperature.
  • the reaction can be run from about one to about 72 hours but usually will be completed in about 3 hours .
  • Tebbe reagent of formula X from about 1 to about 4 equivalents of the Tebbe reagent are employed per equivalent of the keto compound of formula VIII, preferably about 2 equivalents of the Tebbe reagent.
  • the keto compound of formula VIII and the Tebbe reagent of formula X can be reacted in a suitable solvent such as tetrahydrofuran.
  • a suitable solvent such as tetrahydrofuran.
  • the reaction can be performed at from about -78°C to about the reflux temperature of the solvent, preferably at about 0°C during the initial mixing and at about room temperature for the remainder of the reaction.
  • the reaction can be run from about 15 minutes to about 24 hours but usually will be completed in about 30 minutes.
  • the reagent can be prepared by employing from about 2 to about 30 equivalents of zinc powder, from about 2 to about 20 equivalents of diiodomethane, from about 2 to about 4 equivalents of titanium tetrachloride, and from about 0.01 to 1 equivalent of lead powder or lead chloride per equivalent of the keto compound of formula VIII.
  • the preferred reagent contains about 18 equivalents of zinc powder, about 10 equivalents of diiodomethane, about 2 equivalents of titanium tetrachloride, and about 0.09 equivalents of lead chloride per equivalent of the keto compound of formula VIII .
  • This reaction can be performed in a suitable solvent such as tetrahydrofuran, ether or 1, 2-dimethoxyethane, preferably tetrahydrofuran at a temperature of from about -78°C to about the reflux temperature of the solvent, preferably at about room temperature.
  • the reaction can be run from about 1 hour to about 24 hours but usually will be completed in about 3 hours .
  • the methylene compound of formula XI is treated to remove the O-benzyl and Pi guanine protecting groups and give the compound of the formula
  • a mixture of the methylene compound of formula XI, methanol and tetrahydrofuran can be treated with aqueous hydrochloric acid at a temperature of about 50°C to about 60°C for about 3 to 5 hours, the pH is adjusted to about 7 , and the product is extracted with ethyl acetate to give the compound of formula XII .
  • the two benzyl protecting groups can be removed from the compound of formula XII to give the product of formula I in crude form.
  • a suspension of the compound of formula XII in dichloromethane at about -78°C can be treated with a solution of boron trichloride in dichloromethane to remove the benzyl protecting group.
  • the methylene compound of formula XI can be treated to remove only the Pi protecting group and give the compound of the formula
  • a mixture of the methylene compound of formula XI, methanol, and tetrahydrofuran can be treated with aqueous hydrochloric acid at room temperature for about 30 minutes to about 1 hour, the pH is adjusted to 7, and the product is extracted with ethyl acetate to give the compound of formula XIII.
  • the three benzyl protecting groups can then be removed from the compound of formula XIII to give the product of formula I in crude form.
  • a suspension of the compound of formula XIII in dichloromethane at about -78°C can be treated with a solution of boron trichloride in dichloromethane to remove the benzyl protecting groups.
  • the crude product of formula I can be purified by dissolving in methanol and concentrating in vacuo .
  • the pH of the aqueous phase can be basified to a pH of about 7 by adding IN sodium hydroxide.
  • the neutralized aqueous solution can then be concentrated, and the precipitated solid can be filtered, washed with water, dried, and optionally purified on a reverse phase resin column to give the final product of formula I as a crystalline monohydrate .
  • the product of formula I and pharmaceutically acceptable salts thereof are antiviral agents that can be used to treat viral infections in mammalian species such as domesticated animals (e.g. dogs, cats, horses and the like) and humans.
  • mammalian species such as domesticated animals (e.g. dogs, cats, horses and the like) and humans.
  • domesticated animals e.g. dogs, cats, horses and the like
  • the product of formula I is effective against various viruses but in particular is effective against hepatitis B virus.
  • the product of formula I may be administered parenterally (for example, by intravenous, intraperitoneal, or intramuscular injection) orally, or topically from conventional pharmaceutical formulations containing a sufficient amount of the product of formula I or a pharmaceutically acceptable salt thereof to treat the infection.
  • the dosage will, of course, depend upon the severity of the infection, but will likely be in the range of about 1.0 to 50 mg/kg of body weight.
  • the desired dose may be administered from one to several times daily at appropriate intervals .
  • the pinene- borane complex was dried under vacuum yielding about 300 g (71%) of large colorless crystals (Brown et al . , J.0.C, vol. 49, p. 945 - 947, 1984) .
  • the reaction was stirred at -78°C for 1 hour and was then added to a suspension of the borane-pinene complex (300 g, 1.04 mole) in 900 ml of anhydrous tetrahydrofuran at - 78°C, which had been stirred for 3 hours under an argon atmosphere to break up the large crystals, keeping the temperature between -60°C and -78°C.
  • the reaction was stirred for 7 hours at -78°C and then overnight (14 hours) at -20°C.
  • the reaction was warmed to -10°C and with rapid stirring and 270 ml of 3 N sodium hydroxide was added keeping the internal temperature below 0°C.
  • the mixture was stirred at room temperature under argon for 17 hours after which time no starting material remained.
  • the mixture was placed in an ice-water bath and 120 mL of saturated aqueous sodium sulfite was added dropwise keeping the temperature below 20°C. After the addition was complete, the mixture was stirred at room temperature for 1.5 hours. Starch/iodine paper test showed no peroxide presence.
  • the mixture was transferred to a separatory funnel and the layers were separated.
  • the aqueous phase was back-extracted with ethyl acetate (2x) and combined organics (400 mL) were washed with brine, dried (magnesium sulfate) and concentrated to afford the title product (34.34 g) as a light-yellow oil.
  • the product still contains benzyl alcohol that was present in the starting material .
  • the aqueous phase was extracted with ethyl acetate (lx) followed by extraction with dichloromethane (lx) .
  • the combined organics were dried (magnesium sulfate) and concentrated to obtain the crude material (55 g) as a dark-brown oil.
  • the crude product was purified on silica gel (800 g cartridge) in a radially pressurized module (Biotage Corp.) eluting with hexane (3 L) , 10% ethyl acetate-hexane (3 L) and 25% ethyl acetate- hexane (4 L) .
  • the product eluted with 25% ethyl acetate- hexane .
  • Fractions containing product were combined and concentrated to afford pure title product (29.92 g, 83% over two steps) as a light yellow oil.
  • the combined organic phases were filtered through Celite, the Celite pad was washed with ethyl acetate and the combined filtrate (3 L) was washed with water (3x500 mL) , brine (lx) , dried (magnesium sulfate) and concentrated to obtain the crude material (69.1 g) .
  • the crude still contained some 0-benzyl guanine which was removed by filtering a suspension of crude in dichloromethane through a silica gel pad eluting with 5% methanol-dichloromethane.
  • the mixture was diluted with ethyl acetate (1 L) and washed with 5% aqueous sodium bicarbonate (2x100 mL) , water (2x100 L) , brine, dried (magnesium sulfate) and concentrated to afford the crude product.
  • the crude residue was flash chromatographed the first time on silica gel (800 g cartridge) in a radially pressurized module (Biotage Corp.) eluting with 0.5% triethylamine-chloroform (2L) , 1% triethylamine-chloroform (2L) , 1.5% ethanol-chloroform (3L) , 1.5% ethanol-chloroform (3L) , and 2% ethanol-chloroform (IL) . Most of the product eluted with 1% - 1.5% ethanol-chloroform but separation from excess monomethoxy trityl chloride was not achieved and about 5% of product was converted to the starting material from part (d) under the column conditions.
  • a radially pressurized module Biotage Corp.
  • the mixture was diluted with ethyl acetate (1 L) and stirred vigorously with 1.5:1:1 10% aqueous sodium sulfite-saturated aqueous sodium bicarbonate-brine (280 mL) for a period of 1 hour.
  • the phases were separated in a separatory funnel and aqueous phase back-extracted with ethyl acetate (1x100 mL) .
  • the combined organics were washed with brine, dried (magnesium sulfate) and concentrated to afford crude title product (9.8 g, 100% crude yield containing a small amount of impurity) as a light yellow solid.
  • the resulting black mixture was stirred under argon at room temperature over 3 hours and slowly poured into a suspension of dichloromethane (200 mL) and saturated aqueous sodium bicarbonate (400 mL) .
  • the resulting suspension was stirred vigorously and additional saturated aqueous sodium bicarbonate was added (400 mL) as needed to keep the pH basic.
  • the suspension was filtered through Celite and the Celite pad washed with ethyl acetate (4x200 mL) .
  • the two phases in the filtrate were separated and organic again stirred for 30 minutes with 250 mL of saturated aqueous sodium bicarbonate (as the pH had dropped below 7.0 at this point) .
  • the product was further purified on CHP-20 resin column eluting with water (600 mL) , 5% acetonitrile-water (800 mL) , 7.5% acetonitrile-water (300 mL) , 10% acetonitrile-water (600 mL) , 15% acetonitrile-water (300 mL) and 20% acetonitrile-water (300 mL) .
  • Product started eluting with 5% acetonitrile-water but trailed until the end of elution. Fractions were checked by analytical HPLC and all pure fractions were combined and concentrated to afford 1.9 g of the title compound as a white, crystalline solid; m.p. 234 - 236°C (dec.) for the bulk sample and 255°C (dec.) for an analytical sample recrystallized from water.
  • Example 1 The product of Example 1 was also prepared as described below.
  • the temperature of the mixture was not allowed to raise over -60°C during the addition. After the addition was complete, the mixture was stirred at -78°C for 15 minutes and then gradually warmed up to room temperature. After 3 hours stirring, the black solution was poured into a saturated sodium bicarbonte solution (1.0L), stirred for 30 minutes and filtered through a pad of Celite to remove the inorganic materials . The filtrate was diluted with dichloromethane. The organic layer was separated and the aqueous layer was extracted with dichloromethane (2x600ml) . The dichloromethane extracts were combined, washed with brine, dried over anhydrous magnesium sulfate and evaporated in vacuo to give 21g of crude title product with consistent NMR spectra. This reaction was repeated twice using 70 g of cyclopentanone starting material each time and afforded a total of an additional 144 g of title product. This was used in the next step without purification.
  • Nitrogen gas was bubbled with stirring through freshly distilled tetrahydrofuran for a period of one hour.
  • To 2 ml of degassed tetrahydrofuran was added [2R- (2 ⁇ ,3 ⁇ , 5 ⁇ ) ]-5-[2- [[ (4-methoxyphenyl) diphenylmethyl] - amino] -6-phenylmethoxy-9-purin-9-yl] -3- (phenylmethoxy) -2- [ (phenylmethoxy) methyl ] -1-cyclopentanone (0.821 g, 1 mmol) [prepared as described in Example 1(a) through (f)] and the resulting solution was added 2 ml of 0.5 M solution of Tebbe reagent in toluene (Aldrich) via syringe.
  • the turbid light-yellow reaction mixture was stirred for 2 hours at -78°C, for 40 minutes at -20°C, and for 20 minutes at 0°C. TLC showed a single lower Rf product spot .
  • the reaction mixture was recooled to -78°C and methanol (3 ml) was added slowly affording a clear, colorless solution. This solution was warmed to room temperature, concentrated to dryness, and reconcentrated once from methanol to afford 58 mg of crude product as a light tan solid (greater than about 95% purity) .
  • This crude product was dissolved in water and extracted with ether.
  • the pH of the aqueous solution was . adjusted to 7 with aqueous sodium hydroxide.
  • the aqueous solution was applied to a column (2.5 x 5 cm) of HP-20 reverse phase resin and eluted with water (75 ml) , 5% acetonitrile (50 ml) , and 10% acetonitrile (75 ml) .
  • the product was eluted in the 5% - 10% acetonitrile fractions .
  • the product containing fractions were combined and concentrated to afford the title product as a white powdery solid; m.p. >225°C (dec).

Abstract

Improvements in the yield of the antiviral agent of formula (I) are obtained by employing Dess-Martin periodinane to convert the cyclopentol of formula (VI) to the cyclopentanone of formula (VIII) and the methylenation of this cyclopentanone to the compound of formula (XI) by use of a Nysted reagent, Tebbe reagent, or a reagent prepared from zinc powder, diiodomethane, lead powder or lead chloride, and titanium tetrachloride in a suitable solvent.

Description

Improved Process For Preparing The Antiviral Agent
■lS-(lα.3α.4β) l-2-Amino-l,9-Dihvdro-9-
[4-Hvdroxy-3- (Hydroxymethyl) -2-Methylene- cvclopentyll -6H-Purin-6-One
Background of the Invention
Zahler et al . in U.S. Patent 5,206,244 disclose the preparation of hydroxymethyl (methyl-enecyclopentyl)purines and pyrimidines as antiviral agents. Among the compounds disclosed is [IS- (lα, 3α, 4β) ] -2-amino-l, 9-dihydro-9- [4-hydroxy-3- (hydroxy methyl) -2-methylenecyclopentyl] - 6H-purin-6-one .
Brief Summary Of The Invention
This invention is directed to improvements in several steps of the process disclosed by Zahler et al . in U.S. Patent 5,206,244 for preparing the antiviral agent of the formula
Figure imgf000003_0001
One improvement involves the step where the protected guanine substituted cyclopentanol compound of the formula (VI )
Figure imgf000004_0001
wherein Pi is a trityl or substituted trityl protecting group such as monomethoxytrityl or 4, 4 ' -dimethoxytrityl is oxidized to the keto compound of the formula
(VIII)
Figure imgf000004_0002
According to the improved process of this invention, the oxidation is achieved by reacting the cyclopentanol of formula VI with Dess-Martin periodinane having the formula
(VII)
0
II
Figure imgf000004_0003
As a result, the keto compound of formula VIII is obtained in higher yields than in the process of example 1(g) of U.S. Patent 5,206,244.
Another improvement involves the step where the keto compound of formula VIII is converted to the methylene compound of the formula
(XI)
Figure imgf000005_0001
According to the improved process of this invention, methylenation of the keto group is achieved by use of the Nysted reagent having the formula
Figure imgf000005_0002
the Tebbe reagent having the formula
(X)
Figure imgf000005_0003
a reagent prepared from zinc powder, diiodome hane, and lead powder or lead chloride in titanium tetrachloride and a suitable solvent, see Takai et al . , J. Org . Chem., 1994, 59 , p. 2668 - 2670 and the supplementary material. The use of the above methylenation reagents results in the preparation of compound XI in higher yields than in the process of examples 1(h) and l(i) of U.S. Patent 5,206,244.
Detailed Description Of The Invention
The process improvements of this invention result in the preparation of the antiviral agent [IS- (lα, 3α, 4β) ] -
2-amino-1, 9-dihydro-9- [4-hydroxy-
3- (hydroxymethyl-2-methylenecyclopentyl ] -6H-purin- 6-one of formula I in improved yields. This compound . possesses antiviral activity and is currently being evaluated for use in treating hepatitis B viral infections. According to process described in Example 1 of U.S.
Patent 5,206,244 the antiviral agent of formula I is prepared by treating the cyclopentenol of the formula
(ID
Figure imgf000006_0001
with t-butyl hydroperoxide and vanadyl acetate in dry dichloromethane to give the epoxide of the formula (III)
®- H2COH2C- > *~>>χ ==
HO
The epoxide of formula III can then be treated to introduce a benzyl protecting group onto the hydroxy. For example, the epoxide of formula III in tetrahydrofuran can be added to a suspension of sodium hydride in tetrahydrofuran followed by the addition of benzyl bromide and tetrabutyl-ammonium iodide to give the epoxide of the formula
(IV)
Figure imgf000007_0001
The protected epoxide of formula IV can then be reacted with O-benzyl guanine to give the guanine substituted cyclopentanol of the formula
Figure imgf000007_0002
The amino group of the guanine substituted cyclopentanol of formula V can then be protected with trityl or substituted trityl to give the protected guanine substituted cyclopentanol of formula VI. For example, the compound of formula VI wherein Pi is monomethoxytrityl can be obtained by treating a solution of the compound of formula V in dichloromethane with triethylamine followed by p-anisylchlorodiphenylmethane and 4-dimethylamino-pyridine. The compound of formula VI can then be oxidized to keto compound of formula VIII. According to this invention, the yield of the keto compound of formula VIII is increased by employing the Dess-Martin periodinane of formula VII as the oxidizing agent. Thus, the protected guanine substituted cyclopentanol of formula VI can be reacted with from about 1 to about 4 equivalents, preferably about 2 equivalents, of the Dess-Martin periodinane of formula VII at a temperature of from about -20°C to about 40°C, preferably at about room temperature, i.e. about 22 °C. The reaction is performed in a suitable solvent such as dichloromethane, chloroform, 1, 2-dichloroethane, other chlorinated hydrocarbons, or acetonitrile. Preferred solvents include dichloromethane, chloroform, and 1, 2-dichloroethane with dichloromethane being most preferred. Optionally, water or t-butanol can be included in the reaction mixture at up to about 1 equivalent of the Dess-Martin periodinane, preferably about 1 equivalent of t-butanol is included in the reaction mixture. The reaction can be run for about 30 minutes to about 24 hours but will usually be completed in about 2 hours . The keto compound of formula VIII can then be methylenated to the methylene compound of formula XI . According to the process of this invention, the yield of the methylene compound of formula XI is increased by the use of the Nysted reagent of formula IX, the Tebbe reagent of formula X, or the zinc reagent described by Takai et al . (J. Org. Chem., 1994, 5_9_, p. 2668 - 2670 and supplementary material) as the methylenation reagent. The Nysted reagent of formula IX is the preferred methylenation reagent.
When the methylenation is performed with the Nysted reagent of formula IX, from about 1 to about 4 equivalents of the Nysted reagent are employed per equivalent of the keto compound of formula VIII, preferably about 1.3 equivalents of Nysted reagent. Up to about 1 equivalent of titanium tetrachloride per equivalent of the keto compound of VIII can be also included in the reaction mixture, preferably 1 equivalent of titanium tetrachloride. The keto compound of formula VIII and the Nysted reagent of formula IX can be reacted in a suitable solvent such as tetrahydrofuran or hexamethylphosphoramide, preferably tetrahydrofura . The reaction can be kept at a temperature of from about -78°C to about 25°C during the initial mixing and then at from about 0°C to the reflux temperature of the solvent, e.g. 66°C for tetrahydrofuran, preferably at room temperature. The reaction can be run from about one to about 72 hours but usually will be completed in about 3 hours . When the methylenation is performed with the Tebbe reagent of formula X, from about 1 to about 4 equivalents of the Tebbe reagent are employed per equivalent of the keto compound of formula VIII, preferably about 2 equivalents of the Tebbe reagent. The keto compound of formula VIII and the Tebbe reagent of formula X can be reacted in a suitable solvent such as tetrahydrofuran. The reaction can be performed at from about -78°C to about the reflux temperature of the solvent, preferably at about 0°C during the initial mixing and at about room temperature for the remainder of the reaction. The reaction can be run from about 15 minutes to about 24 hours but usually will be completed in about 30 minutes.
When the methylenation is performed using the zinc reagent described by Takai , et al., the reagent can be prepared by employing from about 2 to about 30 equivalents of zinc powder, from about 2 to about 20 equivalents of diiodomethane, from about 2 to about 4 equivalents of titanium tetrachloride, and from about 0.01 to 1 equivalent of lead powder or lead chloride per equivalent of the keto compound of formula VIII. The preferred reagent contains about 18 equivalents of zinc powder, about 10 equivalents of diiodomethane, about 2 equivalents of titanium tetrachloride, and about 0.09 equivalents of lead chloride per equivalent of the keto compound of formula VIII . This reaction can be performed in a suitable solvent such as tetrahydrofuran, ether or 1, 2-dimethoxyethane, preferably tetrahydrofuran at a temperature of from about -78°C to about the reflux temperature of the solvent, preferably at about room temperature. The reaction can be run from about 1 hour to about 24 hours but usually will be completed in about 3 hours . The methylene compound of formula XI is treated to remove the O-benzyl and Pi guanine protecting groups and give the compound of the formula
Figure imgf000010_0001
For example, a mixture of the methylene compound of formula XI, methanol and tetrahydrofuran can be treated with aqueous hydrochloric acid at a temperature of about 50°C to about 60°C for about 3 to 5 hours, the pH is adjusted to about 7 , and the product is extracted with ethyl acetate to give the compound of formula XII .
The two benzyl protecting groups can be removed from the compound of formula XII to give the product of formula I in crude form. For example, a suspension of the compound of formula XII in dichloromethane at about -78°C can be treated with a solution of boron trichloride in dichloromethane to remove the benzyl protecting group.
Alternatively, the methylene compound of formula XI can be treated to remove only the Pi protecting group and give the compound of the formula
Figure imgf000011_0001
For example, a mixture of the methylene compound of formula XI, methanol, and tetrahydrofuran can be treated with aqueous hydrochloric acid at room temperature for about 30 minutes to about 1 hour, the pH is adjusted to 7, and the product is extracted with ethyl acetate to give the compound of formula XIII. The three benzyl protecting groups can then be removed from the compound of formula XIII to give the product of formula I in crude form. For example, a suspension of the compound of formula XIII in dichloromethane at about -78°C can be treated with a solution of boron trichloride in dichloromethane to remove the benzyl protecting groups.
The crude product of formula I can be purified by dissolving in methanol and concentrating in vacuo . The pH of the aqueous phase can be basified to a pH of about 7 by adding IN sodium hydroxide. The neutralized aqueous solution can then be concentrated, and the precipitated solid can be filtered, washed with water, dried, and optionally purified on a reverse phase resin column to give the final product of formula I as a crystalline monohydrate .
The product of formula I and pharmaceutically acceptable salts thereof are antiviral agents that can be used to treat viral infections in mammalian species such as domesticated animals (e.g. dogs, cats, horses and the like) and humans. As set forth in U.S. Patent 5,206,244 the product of formula I is effective against various viruses but in particular is effective against hepatitis B virus.
The product of formula I may be administered parenterally (for example, by intravenous, intraperitoneal, or intramuscular injection) orally, or topically from conventional pharmaceutical formulations containing a sufficient amount of the product of formula I or a pharmaceutically acceptable salt thereof to treat the infection. The dosage will, of course, depend upon the severity of the infection, but will likely be in the range of about 1.0 to 50 mg/kg of body weight. The desired dose may be administered from one to several times daily at appropriate intervals .
The following examples are illustrative of the invention.
Example 1
flS-(lα,3α.4β) l-2-Amino-1.9-dihvdro-9-r4-hvdroxy- 3- (hvdroxymethyl ) -2-methylenecvclopentyπ -6H-purin- 6-one, monohydrate
a) (lS-trans) -2- (Phenylmethoxy) methyl! -3- cvclopenten-1-ol
A solution of 1M borane-tetrahydrofuran complex
(1600 ml, 1.6 mole) was cooled to 0°C under an argon atmosphere and with stirring one equivalent of (1R) - (+) -α-pinene 98% (91% e.e.) (240 g, 1.6 mole) was added over 15 minutes. The mixture was stored at 5°C (no stirring) for 12 hours. A second one equivalent of pinene (240 g, 1.6 mole) was added and the mixture was again stored at 5°C (no stirring) . After approximately 30 minutes, colorless crystals began to form. The mixture was stored for another 12 hours at 5°C and then the supernatant was removed by cannula and dry nitrogen was blown through the flask. The pinene- borane complex was dried under vacuum yielding about 300 g (71%) of large colorless crystals (Brown et al . , J.0.C, vol. 49, p. 945 - 947, 1984) . To a solution of 92% benzyl chloromethyl ether (153 g, 0.9 mole) in 325 ml of anhydrous tetrahydrofuran at -78°C was added a 2 M solution of sodium cyclopentadienylide (450 ml, 0.9 mole) in tetrahydrofuran keeping the internal temperature between -65 °C and -78°C. The reaction was stirred at -78°C for 1 hour and was then added to a suspension of the borane-pinene complex (300 g, 1.04 mole) in 900 ml of anhydrous tetrahydrofuran at - 78°C, which had been stirred for 3 hours under an argon atmosphere to break up the large crystals, keeping the temperature between -60°C and -78°C. The reaction was stirred for 7 hours at -78°C and then overnight (14 hours) at -20°C. The reaction was warmed to -10°C and with rapid stirring and 270 ml of 3 N sodium hydroxide was added keeping the internal temperature below 0°C. This was followed with the careful addition of 135 ml of 30% hydrogen peroxide keeping the internal temperature below +12°C. The reaction mixture was stirred for 1 hour at 0° to +10°C. The excess hydrogen peroxide was destroyed by adding 9 g of sodium bisulfite to the reaction mixture and stirring for 30 minutes (check for peroxide with starch iodide paper and add more bisulfite if necessary) . The addition of 30 g of sodium chloride and 700 ml of ether effected separation of the organic layer. The aqueous layer was extracted with additional ether (2 x 500 ml) . The combined ether extract was washed with brine and dried over magnesium sulfate. Evaporation of the solvents yielded 510 g of crude product as a yellow oil. A 5 g aliquot of the crude reaction mixture was purified on a Merck EM silica column (20:1) eluting with hexane, 5% ethyl acetate/hexane, 10% ethyl acetate/hexane and 15% ethyl acetate/hexane yielding 1.35 grams (75%) of pure product as a colorless oil, [ee = 96.9%].
The crude reaction mixture was dissolved in 1500 ml of hexane and extracted 4 times with 500 ml of 1 M silver nitrate containing 250 ml of methanol. Saturated brine was added to the aqueous solution containing the silver complex. The precipitated silver chloride was filtered and the aqueous layer was extracted with ether (3 x 500 ml) . The silver chloride cake was stirred with ether yielding an additional quantity of product. The combined ether extract was dried over magnesium sulfate. Concentration of the ether extract yielded 118 grams (65%) of the desired alcohol as a yellow oil. [α]D 22 = + 71° (c = 1, chloroform) . b) riS-(lα,2rχ.3β,5α) 1-2-r (Phenylmethoxy) - methyl! -6-oxabicyclo f3.1.01hexan-3-ol
To a solution of the product from part (a) (31.11 g of 76% pure by weight; 23.65 g, 115.93 mmol; contains 24% by weight of benzyl alcohol) in dry dichloromethane (70 mL) was added vanadyl acetate (0.307 g, 1.159 mmol) and the resulting light green solution was placed in a water bath at room temperature. To the solution was added a 3M solution of t-butyl hydroperoxide in isooctane (81.15 mL, 243.46 mmol) dropwise via addition funnel under argon at such a rate to keep the temperature of the reaction mixture under 20°C. Addition was complete in about 30 minutes. The mixture was stirred at room temperature under argon for 17 hours after which time no starting material remained. The mixture was placed in an ice-water bath and 120 mL of saturated aqueous sodium sulfite was added dropwise keeping the temperature below 20°C. After the addition was complete, the mixture was stirred at room temperature for 1.5 hours. Starch/iodine paper test showed no peroxide presence. The mixture was transferred to a separatory funnel and the layers were separated. The aqueous phase was back-extracted with ethyl acetate (2x) and combined organics (400 mL) were washed with brine, dried (magnesium sulfate) and concentrated to afford the title product (34.34 g) as a light-yellow oil. The product still contains benzyl alcohol that was present in the starting material .
c) ris-(lα.2α.3β.5αl 1 -3- (Phenylmethoxy) -2- r (phenyl ethoxy) methyl! -6-oxabicvclo [3.1.01- hexane
60% Sodium hydride dispersion (9.232 g, 230.81 mmol of sodium hydride) was washed with pentane (3x) and the solid was suspended in 300 mL of dry tetrahydrofuran. To the suspension was added dropwise via addition funnel, a solution of the product from part (b) (34.34 g crude; contains about 77.67 mmol of benzyl alcohol and about 16.23 mmol of t-butyl alcohol by proton NMR) in 200 mL of dry tetrahydrof ran at room temperature . Some frothing was observed initially. The addition was complete over 1 hour and the resulting dark-brown suspension was stirred at room temperature under argon for 2 hours . To the mixture was then added benzyl bromide (26.2 mL, 220.32 mmol) via syringe over 5 minutess followed by tetrabutyl ammonium iodide (0.775 g, 2.098 mmol). After 15 minutes of stirring at room temperature, some frothing was observed and the temperature of the mixture rose to 45 °C. The mixture was cooled in an ice-bath and allowed to warm back to room temperature and stirred for 2.5 hours after which time no starting material remained. The mixture was cooled* in an • ice-bath and 1M aqueous ammonium chloride (125 mL) was added dropwise over 10 minutes. The mixture was stirred vigourously for 5 minutes at room temperature and the layers separated. The aqueous phase was extracted with ethyl acetate (lx) followed by extraction with dichloromethane (lx) . The combined organics were dried (magnesium sulfate) and concentrated to obtain the crude material (55 g) as a dark-brown oil. The crude product was purified on silica gel (800 g cartridge) in a radially pressurized module (Biotage Corp.) eluting with hexane (3 L) , 10% ethyl acetate-hexane (3 L) and 25% ethyl acetate- hexane (4 L) . The product eluted with 25% ethyl acetate- hexane . Fractions containing product were combined and concentrated to afford pure title product (29.92 g, 83% over two steps) as a light yellow oil.
d) . IS- (lα.2β .3ct .5β) 1 -5- [2-Amino-6- (phenylmethoxy) -9H-purin-9-yl! -3- (phenylmethoxy) - 2- [ (phenylmethoxy)methyl! cyclopentanol
To a solution of O-benzyl guanine (46.489 g, 192.9 mmol; dried at 50°C overnight in a vacuum oven) in dry dimethylformamide (250 mL) was added lithium hydride (0.772 g, 96.45 mmol) as a solid (some foaming was observed). After stirring the mixture at room temperature for 10 minutes, the mixture was heated at 60°C for 15 minutess followed by addition of a solution of the product from part (c) (29.9 g, 96.45 mmol) in dry dimethylformamide (150 mL) via cannula. The resulting dark-brown solution was stirred at 60°C for 15 minutes and the temperature of the mixture was raised to 125°C over 45 minutes. After 2 hours at 125°C, no starting material remained. The mixture was cooled to room temperature and glacial acetic acid (5.52 mL, 96.45 mmol) was added and mixture was stirred for 10 minutes at room temperature . The mixture was poured into 1200 mL of distilled water and 600 mL of ethyl acetate was added. The two layers were separated (excess unreacted O- benzyl guanine remains suspended as a solid in organic layer) and the aqueous phase was extracted with ethyl acetate (3x500 mL) . The combined organic phases were filtered through Celite, the Celite pad was washed with ethyl acetate and the combined filtrate (3 L) was washed with water (3x500 mL) , brine (lx) , dried (magnesium sulfate) and concentrated to obtain the crude material (69.1 g) . The crude still contained some 0-benzyl guanine which was removed by filtering a suspension of crude in dichloromethane through a silica gel pad eluting with 5% methanol-dichloromethane. The filtrate was concentrated to obtain 51.3 g of crude material which was flash chromatographed on silica gel (800 g cartridge) in a radially pressurized module (Biotage Corp.) eluting with dichloromethane (2 L) , 1% methanol-dichloromethane (2 L) , 2% methanol-dichloromethane (3 L) , 2.5% methanol- dichloromethane (2 L) and 3.5% methanol-dichloromethane (2 L) . Most of the product eluted with 2.5% methanol- dichloromethane and was collected in two batches, 10.34 g (70% purity) and 23.65 g (80% purity). The 80% pure material was combined with product of similar quality obtained from a small-scale reaction to afford 26.9 g of 80% pure material which was again flash chromatographed on silica gel (800 g cartridge) in a radially pressurized module (Biotage Corp. ) eluting with dichloromethane (2 L) , 1% methanol-dichloromethane (2 L) , 2% methanol- dichloromethane (2 L) , 2.5% methanol-dichloromethane (3 L) and 3% methanol-dichloromethane (2 L) . Fractions containing product of greater than 90% purity were combined and concentrated to afford title product (18.86 g, 92% pure) . Yield of the reaction was calculated to be 51% based on total amount of title product after first chromatography .
e) riS-(lα.2β.3α.5β) 1-5-r2-r r (4-MethoxyphenvD- diphenylmethyl! amino! -6- (phenylmethoxy) -9H- purin-yl! -3- (phenylmethoxy) -2- f (phenylmethoxy) methyl! cyclopentanol
To a solution of the product from part (d) (18.8 g, 34.12 mmol) in 250 mL of dry dichloromethane was added triethylamine (8.08 mL, 58 mmol) followed by monomethoxy trityl chloride (11.59 g, 37.53 mmol) and 4-dimethylaminopyridine (0.208 g, 1.706 mmol). The resulting yellow solution was stirred under argon at room temperature for 27 hours after which time TLC indicated only partial conversion to product. An additional amount of monoethoxy trityl chloride (0.55 equiv) , triethylamine (0.85 equiv) and 4-dimethylaminopyridine (0.025 equiv) were added and mixture stirred for an additional 48 hours but no progress in reaction was observed. At this point, the mixture was concentrated in vacuo and taken up in 25 mL of dry dichloromethane and the above quantities of reactants added again (the monomethoxy trityl chloride was added from a fresh, previously unopened bottle) . Some progress in the reaction was observed and additional amounts of the reactants were added (3x) every 1.5 hours until no starting material was detected by TLC. The mixture was diluted with ethyl acetate (1 L) and washed with 5% aqueous sodium bicarbonate (2x100 mL) , water (2x100 L) , brine, dried (magnesium sulfate) and concentrated to afford the crude product.
The crude residue was flash chromatographed the first time on silica gel (800 g cartridge) in a radially pressurized module (Biotage Corp.) eluting with 0.5% triethylamine-chloroform (2L) , 1% triethylamine-chloroform (2L) , 1.5% ethanol-chloroform (3L) , 1.5% ethanol-chloroform (3L) , and 2% ethanol-chloroform (IL) . Most of the product eluted with 1% - 1.5% ethanol-chloroform but separation from excess monomethoxy trityl chloride was not achieved and about 5% of product was converted to the starting material from part (d) under the column conditions. Two batches of material were collected; 22.42 g of monomethoxy trityl chloride contaminated product and 8.49 g of product containing 10% of the starting material of part (d) . The larger batch was flash chromatographed a second time using the above conditions except that the silica gel was flushed with 0.5% triethylamine-chloroform before loading, the compound solvents used for eluting contained 0.5% triethylamine. However, decomposition to the starting material from part (d) was again observed and two batches were collected; 18.49 g of monomethoxy trityl chloride contaminated product and 3.00 g of 50% pure product contaminated with the starting material from part (d) . An ethyl acetate-hexane system was then used for the chromatography to eliminate usage of a solvent such as ethanol. 18.49 g of material contaminated with monomethoxy trityl chloride was eluted with 50% ethyl acetate-hexane (2L with 0.5% triethylamine), 60% ethyl acetate-hexane (2L with 0.5% triethylamine), 75% ethyl acetate-hexane (2L with 0.5% triethylamine), 90% ethyl acetate-hexane (2L with 0.5% triethylamine), and 100% ethyl acetate (4L with 0.5% triethylamine) . Product eluted with 90% ethyl acetate-hexane and fractions containing pure product were concentrated to give 13.67g of pure titled product. A fourth chromatogaphy on silica gel using the ethyl acetate-hexane system described above was carried out on 11.49 g of impure material to give another batch of pure title product (9.48g). Total amount of pure title product after all chromatography was 23.15 g (82% yield) .
f) r2R-(2α.3β.5α)!-5-r2-r r (4-MethoxyphenvD- diphenylmethyll amino! -6- (phenylmethoxy) -9- purine-9-yll -3- (phenylmethoxy) -2- r (phenylmethoxy) methyl! -1-cyclopentanone
To a slurry of Dess-Martin periodinane (5.814 g, 13.71 mmol) in dry dichloromethane (150 mL) was added t-butanol (1.383 mL, 15.077 mmol) and after a stirring under argon for 10 minutes at room temperature, a solution of the product from part (e) (9.4 g, 11.422 mmol) in dry dichloromethane (100 mL) was added via cannula. The slightly yellow mixture was stirred under argon at room temperature for 30 minutes after which time all starting material had been consumed. The mixture was diluted with ethyl acetate (1 L) and stirred vigorously with 1.5:1:1 10% aqueous sodium sulfite-saturated aqueous sodium bicarbonate-brine (280 mL) for a period of 1 hour. The phases were separated in a separatory funnel and aqueous phase back-extracted with ethyl acetate (1x100 mL) . The combined organics were washed with brine, dried (magnesium sulfate) and concentrated to afford crude title product (9.8 g, 100% crude yield containing a small amount of impurity) as a light yellow solid. Conversion of another batch of the product from part (e) (13.67 g, 16.525 mmol) as described above afforded a second batch of title product (13.6 g containing a small amount of impurity). g) riS-(lα.3α.4β) 1 -N- F (4-Methoxyphenyl) - diphenylmethyl 1 -6- (phenylmethoxy) -9- r2-methylene-4- (phenylmethoxy) -3- T (phenylmethoxy) methyl! cvclopentyl! - 9H-purin-2-amine
To a suspension of activated zinc (-325 mesh, 19.45 g, 297.45 mmol) and lead chloride (0.414 g, 1.487 mmol) in dry tetrahydrofuran (300 mL) was added methylene iodide (13.31 mL, 165.25 mmol) under argon at room temperature. No change in temperature was observed during the addition of methylene iodide but after 10 minutes of stirring, the temperature had increased to 30°C at which point the temperature jumped to 65°C and the mixture started boiling. The mixture was cooled in an ice-bath until the temperature dropped and the resulting black suspension was stirred at room temperature for 45 minutes . To the stirred suspension cooled to 0°C was then added 1M titanium tetrachloride in dichloromethane (33.05 mL) slowly via syringe over 15 minutes maintaining the temperature of reaction mixture at 5° to 10°C. The ice-bath was removed and the temperature allowed to rise to room temperature over 45 minutes and stirred for 45 minutes more. To the resulting dark-brown suspension was added a solution of the product from part (f) (crude 13.6 g, 16.525 mmol) in dry tetrahydrofuran (100 mL) via cannula. The resulting black mixture was stirred under argon at room temperature over 3 hours and slowly poured into a suspension of dichloromethane (200 mL) and saturated aqueous sodium bicarbonate (400 mL) . The resulting suspension was stirred vigorously and additional saturated aqueous sodium bicarbonate was added (400 mL) as needed to keep the pH basic. After stirring for 1 hour, the suspension was filtered through Celite and the Celite pad washed with ethyl acetate (4x200 mL) . The two phases in the filtrate were separated and organic again stirred for 30 minutes with 250 mL of saturated aqueous sodium bicarbonate (as the pH had dropped below 7.0 at this point) . After this time, the pH of the organic phase remained at 8.0 and the phases separated. The aqueous phase was back-extracted with ethyl acetate and the combined organics were washed with brine, dried (magnesium sulfate) and concentrated to obtain 13.4 g of the crude residue.
h) riS- (lα, 3α, 4β) 1 -2-Amino-l.9-dihvdro-9- \ 2 - methylene-4- (phenylmethoxy) -3- [ (phenyl- methoxy) ethyl! cvclopentyll -6H-purin-6-one
To a solution of the product from part (g) (8.0 g, 9.768 mmol) in 1 : 1 tetrahydrofuran-methanol (200 mL) was added 2N aqueous hydrochloric (48.84 mL) and solution was stirred at 60°C for 4.5 hours after which time no starting material or intermediate tribenzyl compound remained. The mixture was cooled to room temperature and diluted with water (100 mL) and ethyl acetate (600 mL) . The two phases were stirred vigorously and pH of the mixture adjusted to 7.0 by adding IN sodium hydroxide. A white solid which had precipitated at this point stayed suspended in the organic phase . The two phases were separated and the aqueous phase was back-extracted with ethyl acetate and the combined organics with suspended solid were washed with brine and dried with sodium sulfate. The organic phase and suspended solid were decanted off and the suspension concentrated in vacuo . The product obtained was washed with cold ethyl acetate and dried to afford 4.23 g (92%) of title product as a white solid. A second batch of product from part (g) was coverted as described above to afford 1.7 g (94%) of the title produt which was combined with the first batch and triturated twice with ethyl acetate. The combined material was then dissolved in a mixture of dichloromethane - methanol-chloroform-ethanol (500 mL) , filtered to remove any insoluble material and concentrated to afford 5.75 g of pure title product as a white solid. i ) US- ( lα . 3α . 4β ) 1 -2 -Amino- 1 . 9 -dihvdro-9 -
[4-hvdroxy-3- (hvdroxymethyl) -2-methylene- cvclopentyl! -6H-purin-6-one, monohydrate
To a suspension of the product from part (h) (4.3 g, 9.41 mmol) in dry die1oro ethane (500 mL) cooled to -78°C was added a solution of 1M boron trichloride in dichloromethane (56.46 mL) via syringe over a period of 20 minutes. The resulting yellow turbid mixture was stirred at -78°C under argon for 1 hour and then warmed to -20°C and stirred for 15 minutes after which time no starting material remained. After a total time of 45 minutes at - 20°C, the mixture was cooled back to -78°C and methanol was added slowly (300 mL) . The resulting clear solution was warmed to room temperature and concentrated in vacuo . Additional methanol (500 mL) was added and concentrated repeating* the same process once more to obtain the crude residue. This crude was combined from the crude obtained from treating an additional amount of the product from part (h) (1.372 g, 3 mmol) as described above and the combined material was taken up in water (800 mL) and extracted with ether (2x100 mL) . The aqueous phase was separated and its pH adjusted from 1.95 to 7.0 with the addition of IN sodium hydroxide. The neutralized aqueous solution was concentrated on the rotovap to a volume of 100 mL and the precipitated solid was filtered, washed with cold water and dried to obtain 3.12 g of the product. The product was further purified on CHP-20 resin column eluting with water (600 mL) , 5% acetonitrile-water (800 mL) , 7.5% acetonitrile-water (300 mL) , 10% acetonitrile-water (600 mL) , 15% acetonitrile-water (300 mL) and 20% acetonitrile-water (300 mL) . Product started eluting with 5% acetonitrile-water but trailed until the end of elution. Fractions were checked by analytical HPLC and all pure fractions were combined and concentrated to afford 1.9 g of the title compound as a white, crystalline solid; m.p. 234 - 236°C (dec.) for the bulk sample and 255°C (dec.) for an analytical sample recrystallized from water.
TLC: Rf = 0.31, silica gel; 6:3:1 dichloromethane: methanol : ammonium hydroxide; UV detection HPLC: Purity >99.8% YMC S-3 120A ODS column, 6 x 150 mm; 100% A Isocratic (A = 90% water/methanol + 0.2% phosphoric acid); 215 nm. Retention time = 6.58 minutes. !H NMR (400 MHz, DMSO-d6): δ 10.57 (br s, IH) 7.69 (s, IH)
6.41 (br s, 2H) 5.36 (m, IH) 5.1 (m, IH) 4.89 (s, IH) 4.83 (m, IH) 4.58 (m, IH) 4.22 (m, IH) 3.55 (m, 2H) 2.52 (m, IH) 2.21 (m, IH) 2.04 (m, IH) .
13C NMR (100 MHz, DMSO-d6): δ 156.8, 153.4, 151.4, 151.2, 135.9, 116.2, 109.2, 70.3, 62.9, 55.0, 54.0. Mass Spec (ESI) (M+H)+ = 278; (M-H) _ = 276.
IR (KBr) : 3447, 3183, 2710, 1724, 1632, 1601, 1541, 1487, 1400, 1325, 1167, 1063, 1017 cm"1. [α]o = +33.2° (c = 0.30, H20) . Analysis calc . for C12H15N5O3 •H2O: Calculated: C, 48.81; H, 5.80; N, 23.72; Found: C, 48.81; H, 5.70; N, 23.86.
Example 2
flS-(lα.3α.4β) 1 -2-Amino-1.9-dihvdro-9- r4-hvdroxy-3- (hvdroxymethyl) -2-methylene- cvclopentyll -6H-purin-6-one, monohydrate
The product of Example 1 was also prepared as described below.
a) riS-(lα,3α,4β) 1 -N- T (4-Methoxyphenyl)di- phenylmethyl 1 -6- (phenylmethoxy) —9— T2— methylene-4- (phenylmethoxy) -3- [ (phenyl- methoxy) methyl! cvclopentyl! -9H-purin-2 -amine To a suspension of Nysted reagent (20% by weight in tetrahydrofuran, 70g, 30.67 mmole) in dry tetrahydrofuran (40 ml) at -78°C under argon was slowly added a solution of [2R- (2α,3β,5α) ]-5-[2- [ [ (4-methoxyphenyl)diphenyl- methyl] amino] -6- (phenylmethoxy) -9-purin-9-yl] - 3- (phenylmethoxy) - 2- [ (phenylmethoxy) methyl] -1- cyclopentanone (20 g, 24.33 mmole) [prepared as described in Example 1(a) thorugh (f)] in dry dichloromethane (40 ml) followed by a solution of titanium (IV) chloride (1.0M in dichloromethane, 24.4ml, 24.4mmole). The temperature of the mixture was not allowed to raise over -60°C during the addition. After the addition was complete, the mixture was stirred at -78°C for 15 minutes and then gradually warmed up to room temperature. After 3 hours stirring, the black solution was poured into a saturated sodium bicarbonte solution (1.0L), stirred for 30 minutes and filtered through a pad of Celite to remove the inorganic materials . The filtrate was diluted with dichloromethane. The organic layer was separated and the aqueous layer was extracted with dichloromethane (2x600ml) . The dichloromethane extracts were combined, washed with brine, dried over anhydrous magnesium sulfate and evaporated in vacuo to give 21g of crude title product with consistent NMR spectra. This reaction was repeated twice using 70 g of cyclopentanone starting material each time and afforded a total of an additional 144 g of title product. This was used in the next step without purification.
b) riS- (lα.3α, 4β) 1 -2-Amino-1.9-dihvdro-9- [2-methylene-3- (phenylmethoxy) -4- [ (phenylmethoxy) methyl! cvclopentyl! -6H-purin-6-one
A solution of the product from part (a) (lOg, 12.20 mmole) in methanol (130 ml) and tetrahydrofuran (130 ml) was treated with 2N hydrochloric acid (61 ml) . The solution was heated at 60°C for 4.0 hours. HPLC indicated the reaction was complete. The resulting solution was cooled to room temperature and diluted with ethyl acetate (500 ml) and water (300 ml) . The pH of the solution was then adjusted to 7 with 2N sodium hydroxide. The organic layer was separated. The aqueous layer was extracted with ethyl acetate (2 x 300 ml) . The ethyl acetate extracts were combined, washed with brine, dried over anhydrous magnesium sulfate and evaporated in vacuo to give a gum. This was triturated with ethyl acetate to give 3.7 g of clean title product as a solid with consistent NMR spectra. This reaction was repeated using 155 g of starting material to give an additional 52 g of title product.
c) riS- (lα,3α.4β) 1-2-Amino-1.9-dihvdro-
9- f4-hvdroxy-3- (hvdroxymethyl) 2-methylene- cyclopentyll -6H-purin-6-one, monohydrate
A suspension of the product from part (b) (52 g, 109.8 mmol) in dry dichloromethane (1750 ml) under argon was cooled to -78°C. A solution of boron trichloride (1.0M in dicloromethane, 660 ml, 660 mmole) was added in a period of 30 minutes . The temperature of the mixture was not allowed to raise over -60°C during the addition. After the addition was complete, the mixture was stirred at -78°C for 30 minutes and gradually warmed up to -20°C. After 30 minutes at -20°C, TLC (silica gel, 6: 3: 1 dichloromethane :methanol : ammonium hydroxide) indicated there was no starting materials. The solution was cooled to -78°C and methanol (2.0 L) was slowly added. The resulting clear solution was warmed up to room temperature and concentrated in_vacuo. Additional methanol (2.0 L) was added and concentrated. The residue was diluted with water (500ml) and washed with ethyl ether (2x300ml) and ethyl ether-ethyl acetate (1:1, 2x300ml) . The pH of the aqueous slurry was then adjusted to 7 with 2N sodium hydoxide.The resulting slurry was heated up until it became a homogeneous solution. Charcoal was added to remove color and filtered. The filtrate was concentrated in vacuo to 500ml. The solid was filtered, washed with water (2x100ml), ethyl ether (2x100ml) , ethyl ether-ethyl acetate (1:1, 2x100ml) and acetonitrile (300ml) and dried over phosphorus pentoxide in a high vacuum for 18 hours to give 19.6g of title product; m.p. 234 - 236°C (dec) . TLC: Rf =0.31; Silica gel;
Dichloromethane :methanol : ammonium hydroxide (6:3:1) , UV. Enantiomeric purity (ee) : >98% (Estimated, other isomer could not be found) . HPLC: (Shimadzu HPLC)
YMC S-3 ODS (C-18) 6.0 x 150 mm, gradient 30 min. from 0% B to 100% B (A = 90% H2θ/MeOH + 0.2% H3PO4; B = 90% MeOH/H2θ + 0.2% H3PO4) ; flow rate at 1.5 mL/min. , UV 220, tR = 5.78 min. , (99.3%) . -→-H NMR (400 MHz, DMSO-d6 ) : δ 10.63 (s, IH) , 7.70 (s, IH) ,
6.43 (s, 2H) , 5.36 (m, IH) , 5.12 (s, IH) , 4.88 (broad, IH) , 4.60 (s, IH) , 4.22 (s, IH) , 3.54 (m, 2H) , 2.52 (m, 2H) , 2.22 ( , IH) , 2.04 (m, lH)ppm
13C NMR (400 MHz, DMSO-de): δ 156.8, 153.6, 151.5, 151.2, 136.0, 116.0, 109.4, 70.4, 63.0, 55.2, 54.1ppm. MS: mw = 277, (M-H) " = 276. [α]D = +35° (c = 0.38, water).
Analysis calc ' d for C12H15N5O3 «1.28H20:
Calculated C, 47.99; H, 5.89; N, 23.32; Found: C, 47.94; H, 5.66; N, 23.13.
Example 3
riS-(lα.3α.4β) 1-N-r (4-MethoxyphenvD- diphenylmethyl 1 -6- (phenylmethoxy) -9- f2-methylene-4- (phenylmethoxy) -3- r (phenylmethoxy) methyl! eye1opentyll -9H- purin-2-amine
The conversion of the ketone of Example 1(f) to the methylene product of Example 1(g) and 2(a) was also performed as described below.
Nitrogen gas was bubbled with stirring through freshly distilled tetrahydrofuran for a period of one hour. To 2 ml of degassed tetrahydrofuran was added [2R- (2α,3β, 5α) ]-5-[2- [[ (4-methoxyphenyl) diphenylmethyl] - amino] -6-phenylmethoxy-9-purin-9-yl] -3- (phenylmethoxy) -2- [ (phenylmethoxy) methyl ] -1-cyclopentanone (0.821 g, 1 mmol) [prepared as described in Example 1(a) through (f)] and the resulting solution was added 2 ml of 0.5 M solution of Tebbe reagent in toluene (Aldrich) via syringe. The resulting dark-red mixture was warmed to room temperature and stirred under argon for 30 minutes after which time no starting material remained. The mixture was diluted with ethyl ether (20 ml) and 0. IN sodium hydroxide was added dropwise until evolution of gas had ceased. Anhydrous magnesium sulfate was added, stirred, and the suspension was filtered through Celite®. The Celite® pad was washed with ethyl acetate (4 x 10 ml) and the combined filtrate was concentrated to yield the crude product as a dark-red solid. The crude product was purified by flash chromatography on silica gel eluting with a stepwise gradient of 0% to 40% ethyl acetate-hexane. The desired product eluted with 30% ethyl acetate-hexane and fractions containing pure product were concentrated to afford 0.503 g (60%) of title product as a light-brown solid. Example 4
riS-(lα.3α.4β) !-2-Amino-l,9-dihvdro-9- \ 4-hvdroχy-3- (hvdroxymethyl) -2-methylene- cvclopentyl! -6H-purin-6-one, monohydrate
a) riS-(lα,3α.4β) 1 -6- (Phenylmethoxy) -9- r2- methylene-4- (phenylmethoxy) -3- [ (phenylmethoxy)methyl 1 cvclopentyl 1 -9H-purin-2 -amine
A solution of [IS- (lα, 3α, 4β) ] -N- [ (4- methoxyphenyl) diphenylmethyl] -6- (phenylmethoxy) -9- [2- methylene-4- (phenylmethoxy) -3- [ (phenylmethoxy)methyl ] cyclopentyl] -9H-purin-2-amine (150 mg, 0.183 mmole) [prepared as described in Example 1 (a) through .(f)] in 2 ml of tetrahydrofuran and 1 ml of IN aqueous hydrochloric acid was stirred at room temperature for 30 minutes. TLC confirmed the absence of starting material. About 5 ml of water and 2 ml of ethyl acetate were added to the reaction mixture and then the pH was raised to about 6.8 by the addition of aqueous sodium hydroxide . The layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layer was washed with brine, dried (sodium sulfate) and concentrated. The resulting crude material was chromatographed on a column (2.5 x 20 cm) of silica gel, eluting with a stepwise gradient of ethyl acetate-hexane. The product containing fractions were combined and concentrated to afford 80 mg of pure title product (80% yield) as a colorless oil which later solidified; m.p. 89 - 91°C.
b) riS-(lα.3α.4βπ -2-Amino-l, 9-dihvdro-9- r4-hvdroxy-3- (hvdroxymethyl) -2-methylene- cvclopentyl1 -6H-purin-6-one, monohydrate To a solution of the product from part (a) (70 mg, 0.13 mmole) in dichloromethane (2 ml) at -78°C was added IM boron trichloride (1.3 ml, 1.3 mmole) in dichloromethane dropwise over 1 minute. The turbid light-yellow reaction mixture was stirred for 2 hours at -78°C, for 40 minutes at -20°C, and for 20 minutes at 0°C. TLC showed a single lower Rf product spot . The reaction mixture was recooled to -78°C and methanol (3 ml) was added slowly affording a clear, colorless solution. This solution was warmed to room temperature, concentrated to dryness, and reconcentrated once from methanol to afford 58 mg of crude product as a light tan solid (greater than about 95% purity) .
This crude product was dissolved in water and extracted with ether. The pH of the aqueous solution was . adjusted to 7 with aqueous sodium hydroxide. The aqueous solution was applied to a column (2.5 x 5 cm) of HP-20 reverse phase resin and eluted with water (75 ml) , 5% acetonitrile (50 ml) , and 10% acetonitrile (75 ml) . The product was eluted in the 5% - 10% acetonitrile fractions . The product containing fractions were combined and concentrated to afford the title product as a white powdery solid; m.p. >225°C (dec). TLC: Rf = 0.24; silica gel; chloroform:methanol : aqueous ammonium hydroxide 6:3:1; UV detection. Anal, calc'd for C12H15N5O3 -1.0 H2O:
Calculated: C, 48.81; H, 5.80; N, 23.72; Found: C, 48.70; H, 5.76; N, 23.54.

Claims

What is claimed is
1. A process for preparing the compound of the formula (VIII )
Figure imgf000031_0001
wherein Pi is a trityl or substituted trityl protecting group which comprises oxidizing the cyclopentanol of the formula (VI)
Figure imgf000031_0002
by reacting with the Dess-Martin periodinane of the formula
(VII)
0
Figure imgf000031_0003
2. A process of Claim 1 wherein the cyclopentanol of formula VI is reacted with from about 1 to about 4 equivalents of the Dess-Martin periodinane of formula VII, the reaction is performed at a temperature of from about -20°C to about 40°C, the reaction is performed in a chlorinated solvent such as dichloromethane, chloroform, or 1, 2-dichloroethane, or is performed in acetonitrile, and water or t-butanol can optionally be included in the reaction mixture at up to about 1 equivalent of the Dess- Martin periodinane of formula VII.
3. A process of Claim 2 wherein the cyclopentanol of formula VI is reacted with about 2 equivalents of the Dess-Martin periodinane of formula VII, the reaction is performed at about room temperature, in a solvent selected from dichloromethane, chloroform, and 1 , 2-dichloroethane, and t-butanol is included in the reaction mixture.
4. A process for preparing the compound of the formula (XI)
Figure imgf000032_0001
wherein Pi is a trityl or substituted trityl protecting group which comprises methylenation of the keto compound of the formula (VIII )
Figure imgf000033_0001
by reacting with the Nysted reagent having the formula
Figure imgf000033_0002
the Tebbe reagent having the formula (X)
Figure imgf000033_0003
a reagent prepared from zinc powder, diiodomethane, lead powder or lead chloride, and titanium tetrachloride in a suitable solvent.
5. A process of Claim 4 wherein the methylenation is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Nysted reagent of formula IX in a solvent such as tetrahydrofuran or hexamethylphosphoramide, the reaction mixture includes up to 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII, and the reaction is kept at a temperature of from about -78°C to about 25°C during the initial mixing and at from about 0° to the reflux temperature of the solvent for the remainder of the reaction.
6. A process of Claim 5 wherein about 1.3 equivalents of the Nysted reagent of formula IX are employed per equivalent of the keto compound of formula VIII, about 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII is included in the reaction mixture, and the reaction is performed in tetrahydrofuran .
7. A process of Claim 4 wherein the methylenation is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Tebbe reagent of formula X in a suitable solvent such as tetrahydrofuran, and the reaction is performed at from about -78°C to about the reflux temperature of the solvent.
8. A process of Claim 7 wherein the methylenation is performed by reacting the keto compound of formula VIII with about 2 equivalents of the Tebbe reagent of formula X in tetrahydrofuran, and the reaction is performed at about 0°C during the initial mixing and at about room temperature for the remainder of the reaction.
9. A process of Claim 4 wherein the methylenation is performed by reacting the keto compound of formula VIII with a reagent containing from about 2 to about 30 equivalents of zinc powder, from about 2 to about 20 equivalents of diiodomethane, from about 2 to about 4 equivalents of titanium tetrachloride, and from about 0.01 to about 1 equivalent of lead powder or lead chloride in a suitable solvent such as tetrahydrofuran, ether, or 1,2- dimethoxyethane, and the reaction is performed at a temperature of from about -78°C to about the reflux temperature of the solvent.
10. A process of Claim 9 wherein the methylenation is performed by reacting the keto compound of formula VIII with a reagent containing from about 18 equivalents of zinc powder, about 10 equivalents of diiodomethane, about 2 equivalents of titanium tetrachloride, and about 0.09 equivalents of lead chloride in tetrahydrofuran, and the reaction is performed at about room temperature.
11. A process for preparing the compound of the formula
Figure imgf000035_0001
which comprises :
a) oxidizing the cyclopentanol of the formula
(VI )
Figure imgf000035_0002
wherein Pi is trityl or substituted trityl protecting group with the Dess-Martin periodinane of the formula
(VII)
O
II
Figure imgf000036_0001
to give the keto compound of the formula (VIII)
Figure imgf000036_0002
b) methylenation of the keto compound of formula
VIII by reacting with the Nysted reagent having the formula
Figure imgf000036_0003
the Tebbe reagent having the formula (X)
Figure imgf000037_0001
a reagent prepared from zinc powder, diiodomethane, lead powder or lead chloride, and titanium tetrachloride in a suitable solvent to give the methylene compound of the formula (XI)
Figure imgf000037_0002
c) treating the compound of formula XI with aqueous hydrochloric acid for sufficient time to remove the O-benzyl and Pi guanine protecting groups and give the compound of the formula
Figure imgf000037_0003
d) treating the compound of formula XII with boron trichloride to remove the two benzyl protecting groups and yield the product of formula I.
12. A process of Claim 11 wherein in step (a) the cyclopentanol of formula VI is reacted with from about 1 to about 4 equivalents of the Dess-Martin periodinane of formula VII, the reaction is performed at a temperature of from about -20°C to about 40°C, the reaction is performed in a chlorinated solvent such as dichloromethane, chloroform, or 1, 2-dichloroethane, or is performed in acetonitrile, and water or t-butanol can optionally be included in the reaction mixture at up to about 1 equivalent of the Dess-Martin periodinane of formula VII.
13. A process of Claim 12 wherein in step (a) the cyclopentanol of formula VI is reacted with about 2 equivalents of the Dess-Martin periodinane of formula VII, the reaction is performed at about room temperature, in a solvent selected from dichloromethane, chloroform, and 1,2- dichloroethane, and t-butanol is included in the reaction mixture .
14. A process of Claim 11 wherein the methylenation in step (b) is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Nysted reagent of formula IX in a solvent such as tetrahydrofuran or hexamethylphosphoramide, the reaction mixture includes up to 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII, and the reaction is kept at a temperature of from about -78°C to about 25°C during the initial mixing and at from about 0° to the reflux temperature of the solvent for the remainder of the reaction.
15. A process of Claim 14 wherein in step (b) about
1.3 equivalents of the Nysted reagent of formula IX are employed per equivalent of the keto compound of formula VIII, about 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII is included in the reaction mixture, and the reaction is performed in tetrahydrofuran .
16. A process of Claim 11 wherein the methylanation in step (b) is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Tebbe reagent of formula X in a suitable solvent such as tetrahydrofuran, and where the reaction is performed at from about -78°C to about the reflux temperature of the solvent .
17. A process of Claim 16 wherein the methylenation in step (b) is performed by reacting the keto compound of ■ formula VIII with about 2 equivalents of the Tebbe reagent of formula X in tetrahydrofuran, and the reaction is performed at about 0°C during the initial mixing and at about room temperature for the remainder of the reaction.
18. A process of Claim 11 wherein the methylenation in step (b) is performed by reacting the keto compound of formula VIII with a reagent containing from about 2 to about 30 equivalents of zinc powder, from about 2 to about 20 equivalents of diiodomethane, from about 2 to about 4 equivalents of titanium tetrachloride, and from about 0.01 to about 1 equivalent of lead powder or lead chloride in a suitable solvent such as tetrahydrofuran, ether, or 1,2- dimethoxyethane and the reaction is performed at a temperature of from about -78°C to about the reflux temperature of the solvent.
19. A process of Claim 18 wherein the methylenation in step (b) is performed by reacting the keto compound of formula VIII with a reagent containing from about 18 equivalents of zinc powder, about 2 equivalents of titanium tetrachloride, about 10 equivalents of diiodomethane, and about 0.09 equivalents of lead chloride in tetrahydrofuran, and the reaction is performed at about room temperature.
20. A process for preparing the compound of the formula
Figure imgf000040_0001
which comprises: a) oxidizing the cyclopentanol of the formula
(VI )
Figure imgf000040_0002
wherein Pi is a trityl or substituted trityl protecting group with the Dess-Martin periodinane of the formula
(VII)
0
II
Figure imgf000040_0003
to give the keto compound of the formula (VIII :
Figure imgf000041_0001
b) methylenation of the keto compound of formula VIII by reacting with the Nysted reagent having the formula
Figure imgf000041_0002
the Tebbe reagent having the formula (X)
Figure imgf000041_0003
a reagent prepared from zinc powder, diiodomethane, lead powder or lead chloride, and titanium tetrachloride in a suitable solvent to give the methylene compound of the formula (XI )
Figure imgf000042_0001
c) treating the compound of formula XI with aqueous hydrochloric acid for sufficient time to remove only the Pi protecting group and give the compound of the formula
(XIII )
Figure imgf000042_0002
d) treating the compound of formula XIII with boron trichloride to remove the three benzyl protecting groups and yield the product of formula I.
21. A process of Claim 20 wherein in step (a) the cyclopentanol of formula VI is reacted with from about 1 to about 4 equivalents of the Dess-Martin periodinane of formula VII, the reaction is performed at a temperature of from about -20°C to about 40°C, the reaction is performed in chlorinated solvent such as dichloromethane, chloroform, or 1, 2-dichloroethane, or is performed in acetonitrile, and where water or t-butanol can optionally be included in the reaction mixture at up to about 1 equivalent of the Dess- Martin periodane of formula VII.
22. A process of Claim 21 wherein in step (a) the cyclopentanol of formula VI is reacted with about 2 equivalents of the Dess-Martin periodinane of formula VII, the reaction is performed at about room temperature, in a solvent selected from dichloromethane, chloroform, and 1,2- dichloroethane, and t-butanol is included in the reaction mixture.
23. A process of Claim 20 wherein the methylenation in step (b) is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Nysted reagent of formula IX in a solvent such as tetrahydrofuran or hexamethylphosphoramide, the reaction mixture includes up to 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII, and the reaction is kept at a temperature of from about -78°C to about 25°C during the initial mixing and at from about 0° to the reflux temperature of the solvent for the remainder of the reaction.
24. A process of Claim 23 wherein in step (b) about 1.3 equivalents of the Nysted reagent of formula IX are employed per equivalent of the keto compound of formula VIII, about 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII is included in the reaction mixture, and the reaction is performed in tetrahydrofuran.
25. A process of Claim 20 wherein the methylenation in step (b) is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Tebbe reagent of formula X in a suitable solvent such as tetrahydrofuran, and the reaction is performed at from about -78°C to about the reflux temperature of the solvent.
26. A process of Claim 25 wherein the methylenation in step (b) is performed by reacting the keto compound of formula VIII with about 2 equivalents of the Tebbe reagent of formula X in tetrahydrofuran, and the reaction is performed at about 0°C during the initial mixing and at about room temperature for the remainder of the reaction.
27. A process of Claim 20 wherein the methylenation in step (b) is performed by reacting the keto compound of formula VIII with a reagent containing from about 2 to about 30 equivalents of zinc powder, from about 2 to about 20 equivalents of diiodomethane, from about 2 to about 4 equivalents of titanium tetrachloride, and from about 0.01 to about 1 equivalent of lead powder or lead chloride in a suitable solvent such as tetrahydrofuran, ether, or 1,2- di ethoxyethane , and the reaction is performed at a temperature of from about -78°C to about the reflux temperature of the solvent.
28. A process of Claim 27 wherein the methylenation is performed by reacting the keto compound of formula VIII with a reagent containing from about 18 equivalents of zinc powder, about 10 equivalents of diiodomethane, about 2 equivalents of titanium tetrachloride, and about 0.09 equivalents of lead chloride in tetrahydrofuran, and the reaction is performed at about room temperature.
29. A process for preparing the compound of the formula
Figure imgf000045_0001
which comprises:
a) methylenation of the keto compound of formula
(VIII )
Figure imgf000045_0002
by reacting with the Nysted reagent having the formula
Figure imgf000045_0003
the Tebbe reagent having the formula (X)
Figure imgf000046_0001
a reagent prepared from zinc powder, diiodomethane, lead powder or lead chloride, and titanium tetrachloride in a suitable solvent to give the methylene compound of the formula
(XI)
Figure imgf000046_0002
b) treating the compound of formula XI with aqueous hydrochloric acid for sufficient time to remove the 0- benzyl and Pi guanine protecting groups and give the compound of the formula
Figure imgf000046_0003
c) treating the compound of formula XII with boron trichloride to remove the two benzyl protecting groups and yield the product of formula I.
30. A process of Claim 29 wherein in step (a) the methylenation is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Nysted reagent of formula IX in a solvent such as tetrahydrofuran or hexa ethylphosphoramide, the reaction mixture includes up to 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII, and the reaction is kept at a temperature of from about -78°C to about 25°C during the initial mixing and at from about 0° to the reflux temperature of the solvent for the remainder of the reaction.
31. A process of Claim 30 wherein in step (a) about 1.3 equivalents of the Nysted reagent of formula IX are employed per equivalent of the keto compound of formula VIII, about 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII is included in the reaction mixture, and the reaction is performed in tetrahydrofuran .
32. A process of Claim 29 wherein the methylenation in step (a) is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Tebbe reagent of formula X in a suitable solvent such as tetrahydrofuran, and the reaction is performed at from about -78°C to about the reflux temperature of the solvent.
33. A process of Claim 32 wherein the methylenation in step (a) is performed by reacting the keto compound of formula VIII with about 2 equivalents of the Tebbe reagent of formula X in tetrahydrofuran, and the reaction is performed at about 0°C during the initial mixing and at about room temperature for the remainder of the reaction.
34. A process of Claim 29 wherein the methylenation in step (a) is performed by reacting the keto compound of formula VIII with a reagent containing from about 2 to about 30 equivalents of zinc powder, from about 2 to about 20 equivalents of diiodomethane, from about 2 to about 4 equivalents of titanium tetrachloride, and from about 0.01 to about 1 equivalent of lead powder or lead chloride in a suitable solvent such as tetrahydrofuran, ether, or 1,2- dimethoxyethane, and the reaction is performed at a temperature of from about -78°C to about the reflux temperature of the solvent .
35. A process of Claim 34 wherein the methylenation is performed by reacting the keto compound of formula VIII with a reagent containing from about 18 equivalents of zinc powder, about 10 equivalents of diiodomethane, about 2 equivalents of titanium tetrachloride, and about 0.09 equivalents of lead chloride in tetrahydrofuran, and the reaction is performed at about room temperature.
36. A process for preparing the compound of the formula
Figure imgf000048_0001
which comprises :
methylenation of the keto compound of the formula (VIII )
Figure imgf000049_0001
by reacting with the Nysted reagent having the formula
Figure imgf000049_0002
the Tebbe reagent having the formula (X)
Figure imgf000049_0003
a reagent prepared from zinc powder, diiodomethane, lead powder or lead chloride, and titanium tetrachloride in a suitable solvent to give the methylene compound of the formula (XI )
Figure imgf000050_0001
b) treating the compound of formula XI with aqueous hydrochloric acid for sufficient time to remove only the P protecting group and give the compound of the formula
(XIII )
Figure imgf000050_0002
c) treating the compound of formula XIII with boron trichloride to remove the three benzyl protecting groups and yield the product of formula I .
37. A process of Claim 36 wherein in step (a) the methylenation is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Nysted reagent of formula IX in a solvent such as tetrahydrofuran or hexame hylphosphoramide, the reaction mixture includes up to 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII, and the reaction is kept at a temperature of from about -78°C to about 25°C during the initial mixing and at from about 0° to the reflux temperature of the solvent for the remainder of the reaction.
38. A process of Claim 37 wherein in step (a) about 1.3 equivalents of the Nysted reagent of formula IX are employed per equivalent of the keto compound of formula VIII, about 1 equivalent of titanium tetrachloride per equivalent of the keto compound of formula VIII is included in the reaction mixture, and the reaction is performed in tetrahydrofuran.
39. A process of Claim 36 wherein the methylenation in step (a) is performed by reacting the keto compound of formula VIII with from about 1 to about 4 equivalents of the Tebbe reagent of formula X in a suitable solvent such as tetrahydrofuran, and the reaction is performed at from about -78°C to about the reflux temperature of the solvent.
40. A process of Claim 39 wherein the methylenation in step (a) is performed by reacting the keto compound of formula VIII with about 2 equivalents of the Tebbe reagent of formula X in tetrahydrofuran, and the reaction is performed at about 0°C during the initial mixing and at about room temperature for the remainder of the reaction.
41. A process of Claim 36 wherein the methylenation in step (a) is performed by reacting the keto compound of formula VIII with a reagent containing from about 2 to about 30 equivalents of zinc powder, from about 2 to about 20 equivalents of diiodomethane, from about 2 to about 4 equivalents of titanium tetrachloride, and from about 0.01 to about 1 equivalent of lead powder or lead chloride in a suitable solvent such as tetrahydrofuran, ether, or 1,2- dimethoxyethane and the reaction is performed at a temperature of from about -78°C to about the reflux temperature of the solvent.
42. A process of Claim 41 wherein the methylenation in step (a) is performed by reacting the keto compound of formula VIII with a reagent containing from about 18 equivalents of zinc powder, about 10 equivalents of diiodomethane, about 2 equivalents of titanium tetrachloride, and about 0.09 equivalents of lead chloride in tetrahydrofuran, and the reaction is performed at about room temperature .
PCT/US1997/015007 1996-09-03 1997-08-26 IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE WO1998009964A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40906/97A AU4090697A (en) 1996-09-03 1997-08-26 Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2537896P 1996-09-03 1996-09-03
US60/025,378 1996-09-03

Publications (1)

Publication Number Publication Date
WO1998009964A1 true WO1998009964A1 (en) 1998-03-12

Family

ID=21825687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015007 WO1998009964A1 (en) 1996-09-03 1997-08-26 IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE

Country Status (2)

Country Link
AU (1) AU4090697A (en)
WO (1) WO1998009964A1 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627224B2 (en) 2000-02-29 2003-09-30 Bristol-Myers Squibb Co. Low dose entecavir formulation and use
WO2004052310A2 (en) * 2002-12-11 2004-06-24 Bristol-Myers Squibb Company Process and intermediates for synthesis entecavir
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2005118585A1 (en) * 2004-06-04 2005-12-15 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
WO2007030657A1 (en) * 2005-09-09 2007-03-15 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF [1S-(1α, 3α, 4β)]-2- AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2- METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
CN100379736C (en) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 Preparation process of entecavir
WO2008098471A1 (en) * 2007-02-14 2008-08-21 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory A crystalline form of entecavir, its preparation, pharmaceutical compositions thereof and uses
WO2009026790A1 (en) * 2007-08-23 2009-03-05 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Crystal entecavir fomulation and the preparation method thereof
CN101130542B (en) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 Synthesis method of antiviral nucleoside analogue
CN1964972B (en) * 2004-06-04 2011-04-20 布里斯托尔-迈尔斯斯奎布公司 Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
DE102009060194A1 (en) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Intermediate, useful for treating chronic hepatitis B virus infections, comprises entecavir and an auxiliary material
WO2011076412A1 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Oral form of administration comprising entecavir
WO2011046303A3 (en) * 2009-10-12 2011-10-06 Hanmi Holdings Co., Ltd. Novel method for preparing entecavir and intermediate used therein
CN101693713B (en) * 2009-10-28 2011-11-09 福建广生堂药业有限公司 New crystal system of entecavir, preparation process and medicament application thereof
WO2012006964A1 (en) 2010-07-15 2012-01-19 台州市奥翔医药科技有限公司 Entecavir synthesis method and intermediate compound thereof
CN101531660B (en) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 Industrialization production process of entecavir-monohydrate
EP2514750A1 (en) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co., Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
US8338372B2 (en) 2007-09-20 2012-12-25 Zhejiang Medicine Co., Ltd. Dehydroxy vancomycin, the preparation, pharmaceutical composition and the use
CN101781301B (en) * 2010-01-15 2013-04-10 复旦大学 Method for preparing entecavir
WO2013135165A1 (en) * 2012-03-12 2013-09-19 浙江奥翔药业有限公司 Synthetic intermediate of entecavir and method for preparing same
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8569490B2 (en) 2008-12-26 2013-10-29 Hanmi Science Co., Ltd Intermediate and process for preparing entecavir using same
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8722725B2 (en) 2007-03-23 2014-05-13 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof
US8748495B2 (en) 2009-03-09 2014-06-10 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Method of preparing oil suspensions of carotenoid with low viscosity and high fluidity and use thereof
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
EP2832351A1 (en) 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CN106749249A (en) * 2017-01-13 2017-05-31 信泰制药(苏州)有限公司 The crystal formation of entecavir midbodies
CN106749251A (en) * 2017-01-17 2017-05-31 博瑞生物医药泰兴市有限公司 A kind of synthesis of entecavir midbodies and method of purification
CN106749252A (en) * 2017-01-23 2017-05-31 山东鲁抗医药股份有限公司 A kind of method of purification of entecavir midbodies N8
TWI588146B (en) * 2010-08-30 2017-06-21 浙江奧翔藥業股份有限公司 Synthetic method of entecavir and intermediate compounds thereof
CN108101908A (en) * 2017-12-29 2018-06-01 郑州泰丰制药有限公司 A kind of preparation method of deuterated Entecavir
CN108148061A (en) * 2018-03-14 2018-06-12 湖北广济药业股份有限公司 The industrialized process for preparing of Entecavir
CN110759912A (en) * 2018-07-25 2020-02-07 连云港润众制药有限公司 Preparation method of entecavir intermediate
CN110818714A (en) * 2018-08-14 2020-02-21 连云港润众制药有限公司 Synthetic method of entecavir intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865848A (en) * 1969-10-13 1975-02-11 Searle & Co Methylenation reagent
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865848A (en) * 1969-10-13 1975-02-11 Searle & Co Methylenation reagent
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. ORG. CHEM., 1985, Vol. 50, No. 8, PINE et al., "Carbonyl Methylenation Using a Titanium-Aluminum (Tebbe) Complex", pages 1212-1216. *
J. PRAKT. CHEM., July 1994, Vol 336, C. LAMBERTH, "Tebbe's Reagent: Cp2TiCH2A1CIMe2", pages 632-633. *
J. PRAKT. CHEM., July 1996, Vol. 338, A. SPEICHER et al., "Dess-Martin-Periodinan (DMP)", pages 588-590. *
JOURNAL OF ORGANIC CHEMISTRY, 1990, Vol. 55, ROBINS et al., "Periodinane Oxidation, Selective Primary Deprotection and Remarkably Stereoselective Reduction of Tert-Butyldimethylsilyl-Protected Ribonucleosides. Synthesis of 9-(Beta-D-Xylofuranosyl)Adenine or 3'-Deuterioadenosine from Adenosine", pages *
SYNTHESIS, February 1991, PINE et al., "Ketone Methylenation Using the Tebbe and Wittig Reagents - A Comparison", pages 165-167. *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627224B2 (en) 2000-02-29 2003-09-30 Bristol-Myers Squibb Co. Low dose entecavir formulation and use
US6951844B2 (en) 2001-12-07 2005-10-04 Bristol Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US7034152B2 (en) 2002-12-11 2006-04-25 Bristol-Myers Squibb Company Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN100379746C (en) * 2002-12-11 2008-04-09 布里斯托尔-迈尔斯斯奎布公司 Process for preparing the antiviral agent [1s-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one
JP4726491B2 (en) * 2002-12-11 2011-07-20 ブリストル−マイヤーズ スクイブ カンパニー Antiviral agent [1S- (1α, 3α, 4β)]-2-amino-1,9-dihydro-9- [4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl] -6H-purine-6 -Manufacturing method of ON
JP2006509800A (en) * 2002-12-11 2006-03-23 ブリストル−マイヤーズ スクイブ カンパニー Antiviral agent [1S- (1α, 3α, 4β)]-2-amino-1,9-dihydro-9- [4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl] -6H-purine-6 -Manufacturing method of ON
WO2004052310A3 (en) * 2002-12-11 2005-03-03 Bristol Myers Squibb Co Process and intermediates for synthesis entecavir
WO2004052310A2 (en) * 2002-12-11 2004-06-24 Bristol-Myers Squibb Company Process and intermediates for synthesis entecavir
EP2433941A1 (en) 2002-12-11 2012-03-28 Bristol-Myers Squibb Company Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
JP2010222365A (en) * 2002-12-11 2010-10-07 Bristol Myers Squibb Co METHOD FOR PRODUCING ANTIVIRAL AGENT [1S-(1alpha, 3alpha, 4beta)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
CN102675355B (en) * 2002-12-11 2015-05-06 百时美-施贵宝爱尔兰控股公司 Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN104788485A (en) * 2002-12-11 2015-07-22 百时美-施贵宝爱尔兰控股公司 Process for preparing antiviral agent
CN104788485B (en) * 2002-12-11 2017-10-03 百时美-施贵宝爱尔兰控股公司 The method for preparing antiviral agent
CN102675355A (en) * 2002-12-11 2012-09-19 布里斯托尔-迈尔斯斯奎布公司 Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
US7541460B2 (en) 2002-12-11 2009-06-02 Bristol-Myers Squibb Company Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-3-methylenecyclopentyl]-6H-purin-6-one
US7550619B2 (en) 2002-12-11 2009-06-23 Bristol-Myers Squibb Company Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US7786300B2 (en) 2004-06-04 2010-08-31 Bristol-Myers Squibb Company Process for preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN1964972B (en) * 2004-06-04 2011-04-20 布里斯托尔-迈尔斯斯奎布公司 Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US7968555B2 (en) 2004-06-04 2011-06-28 Bristol-Myers Squibb Company Intermediates in the preparation of entecavir via carbon-silicon oxidation
JP2008501711A (en) * 2004-06-04 2008-01-24 ブリストル−マイヤーズ スクイブ カンパニー Process for producing entecavir and its novel intermediate by carbon-silicon oxidation
WO2005118585A1 (en) * 2004-06-04 2005-12-15 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN100379736C (en) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 Preparation process of entecavir
WO2007030657A1 (en) * 2005-09-09 2007-03-15 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF [1S-(1α, 3α, 4β)]-2- AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2- METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
CN101130542B (en) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 Synthesis method of antiviral nucleoside analogue
WO2008098471A1 (en) * 2007-02-14 2008-08-21 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory A crystalline form of entecavir, its preparation, pharmaceutical compositions thereof and uses
US8937076B2 (en) 2007-02-14 2015-01-20 Zhejiang Medicine Co., Ltd. Xinchang Pharaceutical Factory Crystalline form of entecavir, its preparation and the pharmaceutical composition and uses thereof
US8722725B2 (en) 2007-03-23 2014-05-13 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof
EP2514750A1 (en) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co., Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
WO2009026790A1 (en) * 2007-08-23 2009-03-05 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Crystal entecavir fomulation and the preparation method thereof
US8338372B2 (en) 2007-09-20 2012-12-25 Zhejiang Medicine Co., Ltd. Dehydroxy vancomycin, the preparation, pharmaceutical composition and the use
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8957045B2 (en) 2008-12-23 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8569490B2 (en) 2008-12-26 2013-10-29 Hanmi Science Co., Ltd Intermediate and process for preparing entecavir using same
US8748495B2 (en) 2009-03-09 2014-06-10 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Method of preparing oil suspensions of carotenoid with low viscosity and high fluidity and use thereof
CN101531660B (en) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 Industrialization production process of entecavir-monohydrate
JP2013507436A (en) * 2009-10-12 2013-03-04 ハンミ・サイエンス・カンパニー・リミテッド A novel process for producing entecavir and intermediates used therefor
US8569491B2 (en) 2009-10-12 2013-10-29 Hanmi Science Co., Ltd Method for preparing entecavir and intermediate used therein
CN102596956A (en) * 2009-10-12 2012-07-18 韩美控股株式会社 Novel method for preparing entecavir and intermediate used therein
EP2488522A4 (en) * 2009-10-12 2013-05-29 Hanmi Science Co Ltd Novel method for preparing entecavir and intermediate used therein
CN102596956B (en) * 2009-10-12 2014-09-24 韩美科学株式会社 Novel method for preparing entecavir and intermediate used therein
EP2488522A2 (en) * 2009-10-12 2012-08-22 Hanmi Holdings Co., Ltd. Novel method for preparing entecavir and intermediate used therein
WO2011046303A3 (en) * 2009-10-12 2011-10-06 Hanmi Holdings Co., Ltd. Novel method for preparing entecavir and intermediate used therein
CN101693713B (en) * 2009-10-28 2011-11-09 福建广生堂药业有限公司 New crystal system of entecavir, preparation process and medicament application thereof
WO2011076412A1 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Oral form of administration comprising entecavir
DE102009060194A1 (en) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Intermediate, useful for treating chronic hepatitis B virus infections, comprises entecavir and an auxiliary material
CN101781301B (en) * 2010-01-15 2013-04-10 复旦大学 Method for preparing entecavir
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
EP3483161A1 (en) 2010-07-15 2019-05-15 Zhejiang Ausun Pharmaceutical Co., Ltd. Intermediates used to make entecavir
JP2013532174A (en) * 2010-07-15 2013-08-15 チェーチャン オーサン ファーマシューティカル カンパニー,リミティド Method for synthesizing entecavir and intermediate compound thereof
WO2012006964A1 (en) 2010-07-15 2012-01-19 台州市奥翔医药科技有限公司 Entecavir synthesis method and intermediate compound thereof
TWI588146B (en) * 2010-08-30 2017-06-21 浙江奧翔藥業股份有限公司 Synthetic method of entecavir and intermediate compounds thereof
WO2013135165A1 (en) * 2012-03-12 2013-09-19 浙江奥翔药业有限公司 Synthetic intermediate of entecavir and method for preparing same
WO2015014737A1 (en) 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
EP2832351A1 (en) 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CN106749249A (en) * 2017-01-13 2017-05-31 信泰制药(苏州)有限公司 The crystal formation of entecavir midbodies
CN106749251A (en) * 2017-01-17 2017-05-31 博瑞生物医药泰兴市有限公司 A kind of synthesis of entecavir midbodies and method of purification
CN106749252A (en) * 2017-01-23 2017-05-31 山东鲁抗医药股份有限公司 A kind of method of purification of entecavir midbodies N8
CN108101908A (en) * 2017-12-29 2018-06-01 郑州泰丰制药有限公司 A kind of preparation method of deuterated Entecavir
CN108148061A (en) * 2018-03-14 2018-06-12 湖北广济药业股份有限公司 The industrialized process for preparing of Entecavir
CN110759912A (en) * 2018-07-25 2020-02-07 连云港润众制药有限公司 Preparation method of entecavir intermediate
CN110818714A (en) * 2018-08-14 2020-02-21 连云港润众制药有限公司 Synthetic method of entecavir intermediate

Also Published As

Publication number Publication date
AU4090697A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
WO1998009964A1 (en) IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
KR880002276B1 (en) Process for preparation of anti viral compounds
DK170340B1 (en) Purinylcyclobutanes and trans-2-hydroxymethyl-5-oxabicyclo (2,1,0) pentane derivatives for their preparation
CA1308714C (en) Antiviral compounds
AU695032B2 (en) Purine and guanine compounds as inhibitors of PNP
US8569491B2 (en) Method for preparing entecavir and intermediate used therein
US20040229885A1 (en) Xanthine phosphodiesterase V inhibitors
AU697107B2 (en) 2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)methoxy-1,3- propanediol derivative
CA2618963A1 (en) Xanthine derivatives as selective hm74a agonists
JP2626727B2 (en) 2-Nitroimidazole derivative, process for producing the same and radiosensitizer containing the same as an active ingredient
CN109503628B (en) Synthetic method of tazobactam chiral isomer
JPH0680061B2 (en) Novel purine derivative
KR100232619B1 (en) Cyclopropane derivatives, their preparation and pharmaceutical compositions containing them
RU2198885C2 (en) Derivatives of tricyclic triazolobenzazepine, methods of their synthesis, pharmaceutical composition and method of treatment of allergic diseases, intermediate compounds and methods of their synthesis
CN107312055A (en) A kind of new preparation method of rocuronium
US8658792B2 (en) Carbanucleoside synthesis and novel intermediate compounds useful therein
EP0695755A1 (en) Pyrrolocarbazoles
DE19526163A1 (en) New ganciclovir mono:esters and intermediates
DD255351A5 (en) PROCESS FOR THE PREPARATION OF CARBOCYCLIC PURE NUCLEOSIDES
US20130296558A1 (en) Preparation process of an antiviral drug (entecavir) and intermediates thereof
JPH06206879A (en) Production of guanine-containing antivirus agent, and purinesalts useful therefor
EP0537833A2 (en) Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone from a 2,3-unsaturated-1-cyclopentanylpurinone
EP0330992A2 (en) Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them
US6051711A (en) Synthesis of swainsonine salts
US20060014744A1 (en) Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998512718

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: CA